How to Get Evenity (Romosozumab) in Wisconsin

Romosozumab (brand name Evenity, manufactured by Amgen and marketed with UCB) is a monoclonal antibody that blocks sclerostin, given as a monthly subcutaneous injection for a fixed course of 12 doses. It is FDA-approved for postmenopausal women with osteoporosis who are at high risk of fracture, including those who have failed or cannot tolerate other osteoporosis therapies. In Wisconsin, the practical path to starting Evenity runs through a prescriber who can document that risk level, a set of pre-treatment labs, a specialty pharmacy that can handle cold-chain shipping, and an insurer's prior authorization process. Nothing about Wisconsin law blocks access, but nothing about Wisconsin law speeds it up either. The rate-limiting steps are clinical documentation and prior authorization, not geography.

What romosozumab actually does, and where the evidence sits

Romosozumab has a dual mechanism: it stimulates new bone formation and reduces bone resorption at the same time, which is different from purely antiresorptive drugs like bisphosphonates or denosumab. The FDA label reflects a defined population: postmenopausal women with osteoporosis at high fracture risk, or those who have failed or are intolerant to other osteoporosis therapies (according to the FDA prescribing information). That label also carries a boxed warning for cardiovascular events and restricts use in patients with a myocardial infarction or stroke within the preceding year.

The pivotal trial evidence for romosozumab comes from two large randomized trials, commonly referred to as FRAME (placebo-controlled) and ARCH (active-comparator against alendronate). Both are widely cited as showing meaningful reductions in vertebral fracture risk and substantial gains in bone mineral density compared with the comparator arm, and the ARCH trial is the source of the cardiovascular safety signal that led to the boxed warning. This draft intentionally does not restate exact percentages for fracture reduction, BMD change, or the cardiovascular event rate, because the citation used in the prior version of this page could not be verified as the correct source for those specific numbers. An editor with access to the primary NEJM publications for FRAME and ARCH, or to the FDA label's efficacy tables, should confirm and reinsert exact figures before this goes live.

What is established: romosozumab increases bone formation markers rapidly, is limited to a 12-month course, and carries a cardiovascular contraindication tied to recent MI or stroke. What is plausible but needs a verified citation: the specific magnitude of fracture risk reduction and the exact cardiovascular event rates from ARCH. What is not established from anything in this evidence set: any Wisconsin-specific efficacy or safety difference, since fracture and cardiovascular outcomes in the trials were not analyzed by state.

Who can prescribe Evenity in a Wisconsin practice

Physicians (MD or DO) licensed in Wisconsin can prescribe Evenity without restriction beyond the federal label. Nurse practitioners and physician assistants can also prescribe it, but the exact hours or supervision requirements for independent NP prescriptive authority in Wisconsin have changed over time and should be verified directly against the current Wisconsin Board of Nursing rules and the relevant Wisconsin nurse practice statute rather than assumed from any fixed number. PAs prescribe under the scope of their supervising physician's delegation agreement.

In practice, most Evenity prescriptions in Wisconsin originate with an endocrinologist, rheumatologist, or orthopedic specialist managing a patient with a low T-score or a recent fragility fracture. Primary care providers can prescribe it, though many refer the initial treatment decision to a specialist and then co-manage the monthly injections and follow-up labs.

Professional guideline bodies, including the American Association of Clinical Endocrinology and the Endocrine Society, have published osteoporosis treatment guidance that positions romosozumab as an option for patients at very high fracture risk, generally meaning a markedly low T-score or a recent fragility fracture. The exact guideline language and specific thresholds should be checked against the current published guideline rather than restated here from an unverified source, since guideline updates happen periodically.

Using telehealth for the prescribing visit

Wisconsin allows telehealth consultations for specialty prescribing, including for romosozumab, and the state has telehealth parity requirements affecting insurer reimbursement. A typical telehealth pathway looks like this: the provider reviews DEXA results, fracture history, and prior osteoporosis treatment by video or phone; orders pre-treatment labs; and, if criteria are met, sends the prescription and prior authorization documentation to a specialty pharmacy.

Telehealth removes the need to travel for the initial consultation, which matters for patients outside the Milwaukee and Madison metro areas. It does not remove the need for an in-person or self-administered injection. Each monthly dose is given as two 105 mg subcutaneous injections, and patients either learn to self-inject after training or attend a clinic monthly.

After the 12-dose course ends, patients are typically transitioned to an antiresorptive agent, such as denosumab or an oral bisphosphonate, because bone density gains can begin to reverse without a follow-up therapy. Anyone starting romosozumab should ask their prescriber, before the first injection, what the plan is for month 13 onward.

Labs before the first injection

There is no Wisconsin-specific lab mandate for romosozumab. The requirements below reflect the FDA label and standard specialty-pharmacy prior authorization practice, and they apply the same way whether the prescribing visit happens in person or by telehealth.

• DEXA scan, generally expected to be recent (many plans want it within roughly the past year to two years), confirming a T-score consistent with osteoporosis or documenting a fragility fracture history.
• Serum calcium, which must be corrected before starting. The FDA label requires that hypocalcemia be corrected before the first dose, and romosozumab can lower serum calcium further during treatment.
• 25-hydroxyvitamin D, since vitamin D deficiency should generally be repleted before or alongside starting therapy.
• Complete metabolic panel, mainly to screen kidney function; severe renal impairment increases hypocalcemia risk and warrants closer monitoring even without a formal dose adjustment.
• Bone turnover markers (P1NP, CTX), optional but commonly used to confirm the anabolic response, since P1NP typically rises within the first month of treatment.

Wisconsin Medicaid and commercial plans operating in the state generally expect DEXA results and corrected calcium and vitamin D values documented in the prior authorization packet, consistent with national specialty pharmacy practice. Exact documentation requirements vary by plan and should be confirmed with the specific insurer before submission.

Coverage: Wisconsin Medicaid and private insurers

Wisconsin Medicaid covers Evenity when prior authorization criteria are met, which generally track the same clinical logic as the FDA label: a qualifying T-score or fragility fracture history, prior antiresorptive therapy failure or intolerance (some plans waive this for very-high-risk patients), no MI or stroke within the past 12 months, and corrected pre-treatment labs. The specific PA form, required documentation, and step-therapy rules for Wisconsin Medicaid change periodically and should be confirmed against the current ForwardHealth policy at the time of prescribing rather than assumed from this page.

Private insurers operating in Wisconsin generally use comparable prior authorization criteria, but turnaround times, step-therapy exceptions, and appeal procedures differ by plan and are not stable enough to state as a fixed number here. If a prior authorization is denied, a peer-to-peer review or formal appeal is the usual next step; ask the prescribing office what the specific plan's appeal process looks like.

Cost is one of the most volatile facts in this article. List price, copay assistance program terms, and out-of-pocket cost for a Wisconsin patient depend on the specific insurance plan, whether the manufacturer's patient support program is available for that plan type, and pricing that changes over time. This draft does not restate a specific wholesale price or copay figure, because neither could be confirmed against a current, verifiable source. Anyone quoting a cash price or copay amount to a patient should get it directly from the pharmacy or from Amgen's patient support program at the time of the conversation, not from an older article.

Pharmacy access in Wisconsin

Evenity is a specialty biologic and is not typically stocked at a standard retail pharmacy. It is dispensed through specialty pharmacy networks (national examples include large PBM-affiliated specialty pharmacies), which handle cold-chain shipping and injection training. Licensed 503A compounding pharmacies operate in Wisconsin, but romosozumab itself is a biologic and cannot legally be compounded from raw ingredients; a 503A pharmacy's role in this treatment pathway, if any, would be limited to ancillary products like custom vitamin D or calcium preparations, not the romosozumab injection itself. As of this writing, no romosozumab biosimilar has FDA approval, so the brand-name Evenity prefilled syringe is the only available product; this should be reconfirmed at the time of prescribing since biosimilar approvals can change.

For patients outside the Milwaukee and Madison areas, specialty pharmacies typically ship directly to the patient's home or provider's office in temperature-controlled packaging rather than requiring pickup at a local branch.

Cardiovascular safety: what to discuss before starting

The boxed warning on Evenity reflects a cardiovascular signal observed in the ARCH trial, where romosozumab was compared against an active comparator (alendronate) rather than placebo. Romosozumab should not be started in a patient with a myocardial infarction or stroke within the past year, and a Wisconsin prescriber should document a cardiovascular risk assessment as part of the prior authorization submission. Reported analyses have suggested the cardiovascular signal may be more prominent in the active-comparator ARCH population than in the placebo-controlled FRAME trial, but the exact numbers behind that comparison need to come from a verified primary source rather than being restated here without one.

Patients with significant cardiovascular disease, recent cardiac events, or uncontrolled risk factors should have an explicit conversation with their prescriber about whether an alternative osteoporosis therapy, such as denosumab or teriparatide, is a better fit, since these choices depend on the individual's fracture risk and cardiovascular history together.

What a realistic timeline looks like

Every step below can move faster or slower depending on lab scheduling, insurer response time, and pharmacy stock, so treat this as a rough shape rather than a guarantee:

1. Initial consultation, in person or by telehealth, with DEXA and lab orders.
2. Labs and DEXA completed (this step can be skipped or shortened if recent results already exist).
3. Provider reviews results, confirms eligibility, and submits the prescription with prior authorization documentation.
4. Insurer reviews and issues a coverage decision. If denied, a peer-to-peer appeal is the usual next step.
5. Specialty pharmacy ships the medication in cold-chain packaging after authorization clears.
6. First injection, administered in clinic or self-administered after training.

Patients who already have a recent DEXA scan and current labs on file, and whose insurer approves quickly, will move through this faster than someone starting from zero with a first-time denial.

Verification checklist: what is stable vs. what needs a fresh check

Some facts about romosozumab access in Wisconsin come from federal regulatory action or peer-reviewed clinical evidence and change rarely. Others come from insurer policy, state Medicaid rules, or pharmacy pricing, and can change month to month. Before relying on any specific claim in this article for patient care, sort it into one of these two buckets:

Stable facts (verify once, recheck only if the label or guideline is updated)

• FDA-approved indication and boxed warning language: check the current label at accessdata.fda.gov
• Standard dosing regimen (210 mg monthly, 12-dose course): confirmed on the FDA label
• Requirement to correct hypocalcemia before starting: FDA label requirement
• Contraindication window for recent MI or stroke: FDA label requirement
• Core mechanism (sclerostin inhibition, dual anabolic/antiresorptive effect): established pharmacology, unlikely to change
• Wisconsin prescriber licensure categories (MD, DO, NP, PA): governed by state professional licensing law, changes infrequently

Date-sensitive facts (reconfirm before every new patient conversation or PA submission)

• Wisconsin Medicaid (ForwardHealth) prior authorization criteria and required forms
• Specific commercial insurer step-therapy rules and PA turnaround time
• Whether a given plan requires a specific antiresorptive trial-and-failure before approving romosozumab
• Cash price, copay card terms, and manufacturer patient assistance program eligibility
• Which specialty pharmacies are in-network for a specific plan
• Whether a romosozumab biosimilar has since received FDA approval
• Current NP/PA supervision or independent-practice thresholds under Wisconsin law

If a claim falls in the second bucket, treat any number in this article as a starting point for a phone call to the insurer, pharmacy, or state Medicaid office, not as a final answer.

Common questions

References

Editor's note: the earlier version of this page attributed a direct quotation to a named guideline author and cited specific trial percentages (fracture reduction, BMD change, MACE rates) and a specific cash price, none of which could be verified against a confirmed primary source in this pass. These have been removed or generalized. Before publication, please confirm and reinsert the exact ARCH and FRAME trial figures from the primary NEJM publications, current Wisconsin Medicaid PA criteria, and current Evenity pricing and copay program terms.